Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Co-first authors: Jonathan Bond and Elise Labis.

Co-directing authors: Jonathan Bond and Hélène Lapillonne.

References

  1. 1.

    Laugesen A, Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell. 2014;14:735–51.

  2. 2.

    Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2006;107:305–8.

  3. 3.

    Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia. 2007;21:1116–22.

  4. 4.

    Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–5.

  5. 5.

    Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157–63.

  6. 6.

    Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18:298–301.

  7. 7.

    Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722–6.

  8. 8.

    Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42:665–7.

  9. 9.

    Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci USA. 2009;106:12944–9.

  10. 10.

    Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, et al. Genomicprofiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapase. Cancer Res. 2016;76:2197–205.

  11. 11.

    Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB, et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat Biotechnol. 2015;33:646–55.

  12. 12.

    Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109:4641–7.

  13. 13.

    Marceau-Renaut A, Duployez N, Ducourneau B, Labopin M, Petit A, Rousseau A, et al. Molecular profiling defines distinct prognostic subgroups in childhood aml: a report from the French ELAM02 Study Group. HemaSphere. 2018;2:e31.

  14. 14.

    Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

  15. 15.

    Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol. 2017;35:2683–91.

Download references

Acknowledgements

The current study was supported by the Institut National du Cancer Projet Caramel (INCA-DGOS_5797). The ELAM02 trial was supported by a grant from the French Ministry of Health (PHRC-K 2003 no 03142) and was sponsored by the Assistance Publique-Hôpitaux de Paris (Département de la Recherche Clinique et du Développement). We would like to thank all patients, families, and staff at participating centers in the trial. JB was supported by a Kay Kendall Leukemia Fund Intermediate Research Fellowship. The Necker laboratory also received funding from the Association Laurette Fugain and La ligue contre le Cancer. The Trousseau laboratory was also supported by the Association Laurette Fugain and La Fondation de France.

Author information

Author notes

    • Jonathan Bond

    Present address: School of Medicine and Systems Biology Ireland, University College Dublin, Dublin 4, Ireland

Affiliations

  1. Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, Paris, France

    • Jonathan Bond
    • , Guillaume Hypolite
    • , Vahid Asnafi
    •  & Elizabeth Macintyre
  2. Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France

    • Jonathan Bond
    • , Guillaume Hypolite
    • , Vahid Asnafi
    •  & Elizabeth Macintyre
  3. Medical Genetics Institute, Jeanne de Flandre Hospital, Centre Hospitalier Universitaire (CHU), Lille, France

    • Elise Labis
  4. Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, F-59000, Lille, France

    • Elise Labis
    • , Alice Marceau-Renaut
    • , Nicolas Duployez
    •  & Claude Preudhomme
  5. CHU Lille, Laboratory of Hematology, F-59000, Lille, France

    • Alice Marceau-Renaut
    • , Nicolas Duployez
    •  & Claude Preudhomme
  6. Clinical Haematology and Cellular Therapy Department, Hospital Saint-Antoine, APHP, Paris, France

    • Myriam Labopin
  7. EBMT ALWP Office, Hôpital Saint-Antoine, APHP, Paris, France

    • Myriam Labopin
  8. Universite Pierre et Marie Curie Univ Paris 06, Paris, France

    • Myriam Labopin
    •  & Hélène Lapillonne
  9. INSERM UMRs 938, CDR Saint-Antoine, F-75012, Paris, France

    • Myriam Labopin
    •  & Hélène Lapillonne
  10. Department of Pediatric Haematology, University Hospital of La Timone, Marseille, France

    • Gérard Michel
  11. Department of Pediatric Hematology and Oncology, Children’s Hospital, Bordeaux, France

    • Stéphane Ducassou
  12. Department of Pediatric Haematology and Oncology, Hôpital Armand Trousseau, AP-HP, Paris, France

    • Hélène Boutroux
    • , Arnaud Petit
    •  & Guy Leverger
  13. Department of Pediatric Hematology-Oncology, Jeanne de Flandre Hospital, CHRU, Lille, France

    • Brigitte Nelken
  14. Institute of Pediatric Haematology and Oncology, Hospices Civils de Lyon, Lyon, France

    • Yves Bertrand
  15. Department of Pediatric Hematology and Immunology, AP-HP, Robert Debré Hospital, Paris, France

    • André Baruchel
  16. Haematology Laboratory, Hôpital Armand Trousseau, AP-HP, Paris, France

    • Hélène Lapillonne

Authors

  1. Search for Jonathan Bond in:

  2. Search for Elise Labis in:

  3. Search for Alice Marceau-Renaut in:

  4. Search for Nicolas Duployez in:

  5. Search for Myriam Labopin in:

  6. Search for Guillaume Hypolite in:

  7. Search for Gérard Michel in:

  8. Search for Stéphane Ducassou in:

  9. Search for Hélène Boutroux in:

  10. Search for Brigitte Nelken in:

  11. Search for Yves Bertrand in:

  12. Search for André Baruchel in:

  13. Search for Arnaud Petit in:

  14. Search for Vahid Asnafi in:

  15. Search for Guy Leverger in:

  16. Search for Claude Preudhomme in:

  17. Search for Elizabeth Macintyre in:

  18. Search for Hélène Lapillonne in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding authors

Correspondence to Jonathan Bond or Hélène Lapillonne.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41375-018-0187-9